Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
07/2000
07/19/2000CN1054523C Ningshen medicinal composition for treating depressive psychosis
07/19/2000CN1054506C Pharmaceutical composition use
07/18/2000US6090945 Tetrahydro-beta-carbolines
07/18/2000US6090840 Peptidyl compounds having MMP and TNF inhibitory activity
07/18/2000US6090837 Substituted hydrochromenopyrroles
07/18/2000US6090823 Administering n,n'-propylenedinicotinamide
07/18/2000US6090818 Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
07/18/2000US6090816 Antiasthma agents
07/18/2000US6090812 Therapy for psychological, central nervous system disorders
07/18/2000US6090811 Analgesic
07/18/2000US6090808 Dimeric piperidine, tetrahydropyridine and piperazine derivatives
07/18/2000US6090807 Use of heterocyclic compounds
07/18/2000US6090778 Neurturin and related growth factors
07/18/2000US6090775 Treatment of neurological conditions by an interleukin-1 inhibiting compound
07/18/2000US6090612 Polynucleotide sequence coding a phosphatase enzymes; a diagnostic tool for monitoring enzyme activity in sample; for treatment of nervous system disorders, cardiovascular disorders and tumors; antitumor agents
07/18/2000US6090583 Expression system in compatible host cell of a polynucleotide which produces a metalloprotease; diagnosis and treatment of asthma, disorders of leukotriene metabolism; anticarcinogenic agents; antiinflammatory/antidiabetic/antiarthritic agents
07/18/2000US6090579 Human SDR2 cDNA clone
07/18/2000US6090544 Screening for compounds capable of activating osteogenic protein-1-responsive transcription activating element by transforming cell with dna of element linked to reporter gene, exposing cell to compound, determining gene expression
07/18/2000US6090410 Dry mix formulation for bisphosphonic acids
07/18/2000US6090405 Multilayer; backing layer and pressure sensitive adhesive
07/18/2000US6090382 Human antibodies that bind human TNFα
07/18/2000CA2295471A1 Opioid analgesics with controlled active substance release
07/18/2000CA2295469A1 Analgesic with controlled active substance release
07/18/2000CA2045142C Process for the preparation and purification of a mixture of glycosphingolipids, free from contamination by non-conventional viruses
07/18/2000CA2017376C Diarylstyrylquinoline diacids
07/18/2000CA2003289C Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders
07/13/2000WO2000040742A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
07/13/2000WO2000040733A1 Human cyclic nucleotide pdes
07/13/2000WO2000040716A2 Soluble receptor br43x2 and methods of using them for therapy
07/13/2000WO2000040714A2 Therapeutic phosphodiesterase inhibitors
07/13/2000WO2000040699A2 Astrocytes, their preparation and uses thereof
07/13/2000WO2000040612A1 Insulin-like growth factor (igf) i mutant variants
07/13/2000WO2000040581A1 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
07/13/2000WO2000040580A1 3,4-dihydro-2h-benzo[1,4]oxazinyl-methyl[3-(1h-indol-3-yl)-alkyl]-amines
07/13/2000WO2000040579A1 New 1,4-disubstituted cyclohexane derivatives for the treatment of depression
07/13/2000WO2000040578A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
07/13/2000WO2000040576A2 Thiopyran compounds as inhibitors of mmp
07/13/2000WO2000040574A1 1,4-diazacycloheptane compounds, process for their preparation, and their use as medicaments
07/13/2000WO2000040572A1 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands
07/13/2000WO2000040565A1 Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
07/13/2000WO2000040560A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
07/13/2000WO2000040554A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
07/13/2000WO2000040247A1 2-oxy-benzoxazinone derivatives for the treatment of obesity
07/13/2000WO2000040244A1 Use of phanquinone for the treatment or prevention of memory impairment
07/13/2000WO2000040243A1 Novel compounds
07/13/2000WO2000040241A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
07/13/2000WO2000040228A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
07/13/2000WO2000040225A2 Inhibition of tnf activity
07/13/2000WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
07/13/2000WO2000027363B1 Aerosols comprising nanoparticle drugs
07/13/2000WO2000024897B1 Cell surface molecule-induced macrophage activation
07/13/2000WO2000024741A3 Dihydropyridine compounds and their use as potassium channel openers
07/13/2000WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases
07/13/2000WO2000022118A3 Non-desensitizing ampa-receptors
07/13/2000WO2000021927A3 Pyrrole-2,5-diones as gsk-3 inhibitors
07/13/2000WO2000018801A3 Ncam binding compounds
07/13/2000WO2000018351A3 Aglyco products and methods of use
07/13/2000WO2000015208A3 New use of immunosupressants for mmp-mediated diseases
07/13/2000WO2000015204A3 Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers
07/13/2000WO2000013648A3 Method for the preparation of citalopram
07/13/2000WO2000010958A9 Vitamin d3 mimics
07/13/2000WO2000008020A3 Tricyclic carboxamides
07/13/2000WO1999058096A9 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
07/13/2000DE19933939A1 Ausnutzung zelleigener Transportsysteme zum Transfer von Nukleinsäuren durch die Kernhülle Utilization of cellular transport systems for the transfer of nucleic acids by the nuclear envelope
07/13/2000DE19917838A1 Composition for treating prion or other neurodegenerative diseases, comprises a peptide that inhibits unfolding of the prion to its pathological isoform
07/13/2000DE19900743A1 Neue komplexbildende Proteine New complexing proteins
07/13/2000DE19900674A1 Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung Binding partners for 5-HT5 receptors in migraine treatment
07/13/2000DE19900673A1 Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders
07/13/2000DE19900544A1 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie Use of compounds of formula I for the prophylaxis and therapy of cerebral ischemia
07/13/2000CA2753331A1 Soluble receptor br43x2 and methods of using
07/13/2000CA2359989A1 1-phenyl-4-(1-¬2-aryl|cyclopropyl) methylpiperazines: dopamine receptor ligands
07/13/2000CA2358939A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
07/13/2000CA2358851A1 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
07/13/2000CA2358586A1 Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
07/13/2000CA2357950A1 Therapeutic phosphodiesterase inhibitors
07/13/2000CA2357874A1 Cyclic compound
07/13/2000CA2357146A1 Human cyclic nucleotide pdes
07/13/2000CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
07/13/2000CA2355967A1 Astrocytes, their preparation and uses thereof
07/13/2000CA2355361A1 New 1,4-disubstituted cyclohexane derivatives for the treatment of depression
07/13/2000CA2355342A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
07/13/2000CA2355308A1 3,4-dihydro-2h-benzo¬1,4|oxazinyl-methyl¬3-(1h-indol-3-yl)-alkyl|-amines
07/12/2000EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases
07/12/2000EP1018512A1 Novel basic derivatives of benz(e)isoindol-1-ones and pyrrolo(3,4-c)quinolin-1-ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use
07/12/2000EP1018511A1 Isochroman compounds and their production process
07/12/2000EP1018506A1 Substituted alkyltetramine derivatives
07/12/2000EP1018341A1 Antistress agents and functional foods
07/12/2000EP1018339A1 Therapeutic agent for intractable vasculitis
07/12/2000EP1017838A2 Expression of genes in hematopoietic stem cells in hischaemic conditions
07/12/2000EP1017823A2 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
07/12/2000EP1017808A2 53bp2 complexes
07/12/2000EP1017713A1 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
07/12/2000EP1017711A2 Monocyclic compounds with four bifunctional residues having nk-2 antagonist action
07/12/2000EP1017697A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
07/12/2000EP1017696A1 Acidic addition salts of morphine alkaloids and the application thereof
07/12/2000EP1017694A2 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives
07/12/2000EP1017693A1 Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
07/12/2000EP1017678A1 1,5-diphenylpyrazole derivatives
07/12/2000EP1017673A1 Specific immunophilin ligands useful as anti-asthmatic, anti-allergic, anti-rheumatic, immunosuppressive, antipsoriatic and neuroprotective agents
07/12/2000EP1017672A1 New npy antagonists
1 ... 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 ... 1833